Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc    MYL   US6285301072

MYLAN INC (MYL)

68
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/23/2015 01/26/2015 01/27/2015 01/28/2015 01/29/2015 Date
54.21(c) 56.8(c) 56.295(c) 55.24(c) 54.885(c) Last
3 124 194 6 471 755 3 883 101 3 501 934 3 470 665 Volume
-0.42% +4.78% -0.89% -1.87% -0.64% Change
More quotes
Company
Mylan, Inc. is a generic and specialty pharmaceuticals company, through its subsidiaries, which develops, manufactures, markets and distributes pharmaceuticals.The company operates its business through two segments: Generics & Specialty.The Generics segment primarily develops, manufactures, sells... 
Sector
Pharmaceuticals
Calendar
01/29Shareholder meeting
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | MYL | US6285301072 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 7 722 M
EBIT 2014 1 997 M
Net income 2014 1 229 M
Debt 2014 7 597 M
Yield 2014 -
Sales 2015 9 846 M
EBIT 2015 2 770 M
Net income 2015 1 936 M
Debt 2015 6 580 M
Yield 2015 -
PER 2014 19,43
PER 2015 14,79
EV / Sales 2014 3,64x
EV / Sales 2015 2,75x
Capitalization 20 542 M
More Financials
Latest news on MYLAN INC
01/29 MYLAN : Submission of Matters to a Vote of Security Holders, Other Events, Finan..
01/29 ABBOTT LABORATORIES : Mylan says shareholders approve Abbott business purchase
01/29DJAbbott Laboratories Profit Grows 54%
01/28 MYLAN : Other Events (form 8-K)
01/28DJEU Approves Three-Part Deal Between Novartis, GlaxoSmithKline
01/26 MYLAN : Expands Hepatitis C Licensing Agreement with Gilead to Include Investiga..
01/23 Mylan Launches Generic Epivir-HBV® Tablets
01/23 NATCO PHARMA : Us apex court rethink on copaxone patent, a blow to generics make..
More news
Sector news Pharmaceuticals - NEC
02:27aDJNOVO NORDISK A/S : 4Q Net Profit Beats Estimates
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29 Valeant to buy Dendreon's prostate cancer vaccine Provenge
Plus d'actualités du secteur Pharmaceuticals - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF